AMCP is your partner in navigating AI’s transformative potential—ensuring patient-centered, ethically sound, and strategically aligned implementation across pharmacy practice and policy.
JMCP Outsert - Exploring Opportunities to Improve the Quality of Life for Those with Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive, and fatal neurodegenerative disease characterized by loss of motor neurons in the brain and spinal cord. The etiology of ALS is unknown, however it is thought to be due to a combination of genetic predisposition, environmental exposures, and agingrelated dysfunction. The clinical presentation of ALS varies depending on which motor neurons are affected. ALS commonly presents with localized weakness that progresses to muscle paralysis, respiratory failure, and death.
Additionally, approximately 30% of patients develop some form of behavioral impairment. In the United States, it is estimated that up to 32,000 people are living with ALS. The greatest risk factor for developing ALS is age, with the highest prevalence of symptom onset occurring between 55 and 75 years of age. The average life expectancy is two to five years after symptom onset and as the disease progresses there is significant caregiver burden. Current treatments for ALS are largely focused on supportive care. Typically, treatment includes a combination of therapies along with durable medical equipment (DME) to help preserve quality of life as long as possible.
Related
Retinal diseases in patients with diabetes pose signi cant challenges for health care systems. With a high treatment burden and advances in durable therapies, managed care organizations can optimize patient care by addressing coverage barriers that impact timely treatment with anti-VEGF therapies. This roadmap outlines essential points to better retinal disease management and improve treatment for populations of patients with diabetes at high risk for blindness.
View our webinar on Managed Care Approaches to Address Unmet Patient Needs in Multiple Sclerosis (MS), a disease affecting nearly 1 million people in the U.S. Despite advancements in treatment, significant gaps remain in access, affordability, and comprehensive care.
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
